BOFA ON BIOCON
Maintain Buy, TP 435 vs 400
USFDA clears both Malaysia and Benguluru facility
To increase confidence for upcoming bio-similar launch pipeline
Annualized revenue to increase from $1bn in H1FY25 to $1.2bn in FY26
Deleveraging and new launch performance now in focus